Cargando…

VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer

Although probiotics have shown success in preventing the development of experimental colitis-associated colorectal cancer (CRC), beneficial effects of interventional treatment are relatively unknown. Here we show that interventional treatment with VSL#3 probiotic alters the luminal and mucosally-adh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arthur, Janelle C., Gharaibeh, Raad Z., Uronis, Joshua M., Perez-Chanona, Ernesto, Sha, Wei, Tomkovich, Sarah, Mühlbauer, Marcus, Fodor, Anthony A., Jobin, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792409/ https://www.ncbi.nlm.nih.gov/pubmed/24100376 http://dx.doi.org/10.1038/srep02868

Ejemplares similares

Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer
por: Arthur, Janelle C., et al.
Publicado: (2014)

Dietary iron variably modulates assembly of the intestinal microbiota in colitis-resistant and colitis-susceptible mice
por: Ellermann, Melissa, et al.
Publicado: (2019)

Gut microbiota maturation during early human life induces enterocyte proliferation via microbial metabolites
por: Dougherty, Michael W., et al.
Publicado: (2020)

Modulation of the Intestinal Microbiota Alters Colitis-Associated Colorectal Cancer Susceptibility
por: Uronis, Joshua M., et al.
Publicado: (2009)

Microbiota and cancer immunotherapy: in search of microbial signals
por: Gharaibeh, Raad Z, et al.
Publicado: (2019)

The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

Human Colon Mucosal Biofilms and Murine Host Communicate via Altered mRNA and microRNA Expression during Cancer
por: Tomkovich, Sarah, et al.
Publicado: (2020)

Microbial networking in cancer: when two toxins collide
por: Tomkovich, Sarah, et al.
Publicado: (2018)

Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice
por: Wang, Chun-Sai-Er, et al.
Publicado: (2018)

Correction: Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases
por: Cheng, Fang-Shu, et al.
Publicado: (2020)

Probiotic Therapy With VSL#3(®) in Patients With NAFLD: A Randomized Clinical Trial
por: Derosa, Giuseppe, et al.
Publicado: (2022)

Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis
por: Dang, Xiaofei, et al.
Publicado: (2020)

Probiotic mixture VSL#3 prevents ulcerative colitis-associated carcinogenesis in mice and cells by regulating the inflammatory and Wnt/β-catenin pathway
por: Li, Wenbin, et al.
Publicado: (2022)

Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”
por: Sang, Li-Xuan
Publicado: (2021)

Probiotic colonization dynamics after oral consumption of VSL#3(®) by antibiotic-treated mice
por: Theriot, Casey, et al.
Publicado: (2022)

Mechanism of Probiotic VSL#3 Inhibiting NF-κB and TNF-α on Colitis through TLR4-NF-κB Signal Pathway
por: WANG, Hui, et al.
Publicado: (2019)

Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
por: Rashid, Sherzad K., et al.
Publicado: (2014)

Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2013)

PReS-FINAL-2074: The role of the probiotic VSL-3 as adjuvant therapy in patients with undifferentiated spondyloarthritis (ERA)
por: Vidovic, M, et al.
Publicado: (2013)

Correction: Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
Publicado: (2014)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome
por: Distrutti, Eleonora, et al.
Publicado: (2013)

Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation
por: Kim, Seong-Eun, et al.
Publicado: (2015)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

The Probiotic VSL#3(®) Does Not Seem to Be Efficacious for the Treatment of Gastrointestinal Symptomatology of Patients with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Calandre, Elena P., et al.
Publicado: (2021)

Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis
por: Friederich, Pieter, et al.
Publicado: (2011)

Development of omics‐based protocols for the microbiological characterization of multi‐strain formulations marketed as probiotics: the case of VSL#3
por: Mora, Diego, et al.
Publicado: (2019)

Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome
por: Boonma, Prapaporn, et al.
Publicado: (2021)

Correction: The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2022)

Heat-killed VSL#3 Ameliorates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis in Rats
por: Sang, Li-Xuan, et al.
Publicado: (2013)

Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP
por: Distrutti, Eleonora, et al.
Publicado: (2014)

Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial
por: Sinha, Anju, et al.
Publicado: (2015)

Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(−/−) mice
por: Chan, Yee Kwan, et al.
Publicado: (2016)

Probiotic Bacteria Produce Conjugated Linoleic Acid Locally in the Gut That Targets Macrophage PPAR γ to Suppress Colitis
por: Bassaganya-Riera, Josep, et al.
Publicado: (2012)

The Probiotic Mixture VSL#3 Dampens LPS-Induced Chemokine Expression in Human Dendritic Cells by Inhibition of STAT-1 Phosphorylation
por: Mariman, Rob, et al.
Publicado: (2014)

Microbes and colorectal cancer: is there a relationship?
por: Uronis, J.M., et al.
Publicado: (2009)

Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin
por: He, Zhen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tnnfq1o2bcflihtll9kv98e9e7